Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Loïc Raffray & Loïc Guillevin. (2020) Rituximab treatment of ANCA-associated vasculitis. Expert Opinion on Biological Therapy 20:8, pages 899-910.
Read now
Read now
Rbab Taha, Hadeel El-Haddad, Abdulqader Almuallim, Fatma Alshaiki, Elaf Obaid & Hani Almoallim. (2017) Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Open Access Rheumatology: Research and Reviews 9, pages 201-214.
Read now
Read now
Nils Venhoff, Lena Niessen, Matthias Kreuzaler, Antonius G. Rolink, Fabian Hässler, Marta Rizzi, Reinhard E. Voll & Jens Thiel. (2014) Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity 47:6, pages 401-408.
Read now
Read now
Shawn Shetty & A. R. Ahmed. (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:8, pages 487-496.
Read now
Read now
JW Gregersen, A Chaudhry & DRW Jayne. (2013) Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scandinavian Journal of Rheumatology 42:3, pages 207-210.
Read now
Read now
Articles from other publishers (21)
Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri & Soheil Tavakolpour. (2022) The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology 11:12, pages 1767.
Crossref
Crossref
Timo Burster, Zhadyra Mustafa, Dinara Myrzakhmetova, Anuar Zhanapiya & Michal Zimecki. (2021) Hindrance of the Proteolytic Activity of Neutrophil-Derived Serine Proteases by Serine Protease Inhibitors as a Management of Cardiovascular Diseases and Chronic Inflammation. Frontiers in Chemistry 9.
Crossref
Crossref
Vincenzo G Menditto, Giulia Rossetti, Diletta Olivari, Alessia Angeletti, Marco Rocchi, Armando Gabrielli & Giovanni Pomponio. (2021) Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology 60:4, pages 1640-1650.
Crossref
Crossref
Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Yuichi Ishikawa, Maiko Yoshikawa, Kei Sakata, Shigeru Iwata, Ippei Miyagawa, Kazuhisa Nakano & Yoshiya Tanaka. (2020) Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research & Therapy 22:1.
Crossref
Crossref
Clémence Thery-Casari, Romain Euvrard, Sabine Mainbourg, Stéphane Durupt, Quitterie Reynaud, Isabelle Durieu, Alexandre Belot, Hervé Lobbes, Natalia Cabrera & Jean-Christophe Lega. (2020) Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmunity Reviews 19:5, pages 102505.
Crossref
Crossref
E L. Nasonov, T. V. Beketova, L. P. Ananyeva, V. I. Vasilyev, S. K. Solovyev & A. S. Avdeeva. (2019) PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice 57, pages 1-40.
Crossref
Crossref
Gizem Ayan, Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Huri Ozdogan, Sebahattin Yurdakul & Vedat Hamuryudan. (2018) Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International 38:4, pages 607-622.
Crossref
Crossref
Ilias N. Lazarou, Axel Finckh, Lara Fischer, Camillo Ribi, Danielle Gascon, Jörg D. Seebach & Pierre-André Guerne. (2017) Un faible nombre préalable de lymphocytes B n’est pas un facteur de risque d’infection chez les patients traités par rituximab pour des maladies auto-immunes : étude observationnelle. Revue du Rhumatisme 84:2, pages 138-144.
Crossref
Crossref
Emilio Besada. (2016) Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Frank Hill, Jennifer Yonkof, Sri K. Chaitanya Arudra, Jean Thomas & Nezam Altorok. (2016) Successful Treatment of ANCA-Associated Vasculitis in the Setting of Common Variable Immunodeficiency Using Rituximab. American Journal of Therapeutics 23:5, pages e1239-e1245.
Crossref
Crossref
Ilias Lazarou, Axel Finckh, Lara Fischer, Camillo Ribi, Danielle Gascon, Jörg D. Seebach & Pierre-André Guerne. (2016) Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study. Joint Bone Spine 83:2, pages 191-197.
Crossref
Crossref
David A. Cabral & Kimberly Morishita. 2016. Textbook of Pediatric Rheumatology. Textbook of Pediatric Rheumatology
484
499.e8
.
A. Parrot, M. Fartoukh & J. Cadranel. (2015) Hémorragie intra-alvéolaire. Revue des Maladies Respiratoires 32:4, pages 394-412.
Crossref
Crossref
F. Alberici & D. R. W. Jayne. (2013) Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrology Dialysis Transplantation 29:6, pages 1151-1159.
Crossref
Crossref
A. Knight, H. Hallenberg & E. Baecklund. (2013) Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series. Clinical Rheumatology 33:6, pages 841-848.
Crossref
Crossref
Preena Uppal, Jonny Taitz, Brynn Wainstein, Marlene Soma, Yvonne Belessis & Paul Gray. (2014) Refractory otitis media: An unusual presentation of childhood granulomatosis with polyangiitis. Pediatric Pulmonology 49:3, pages E21-E24.
Crossref
Crossref
Lucía Silva-Fernández, Estíbaliz Loza, Víctor M. Martínez-Taboada, Ricardo Blanco, Íñigo Rúa-Figueroa, José María Pego-Reigosa & Santiago Muñoz-Fernández. (2014) Biological therapy for systemic vasculitis: A systematic review. Seminars in Arthritis and Rheumatism 43:4, pages 542-557.
Crossref
Crossref
Emilio Besada, Wenche Koldingsnes & Johannes C. Nossent. (2013) Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology 52:11, pages 2041-2047.
Crossref
Crossref
Emilio Besada & Johannes C. Nossent. (2013) Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?. Clinical Rheumatology 32:11, pages 1677-1681.
Crossref
Crossref
EMILIO BESADA & JOHANNES C. NOSSENT. (2013) Infection Risks During Longterm Rituximab Therapy Change Over Time. The Journal of Rheumatology 40:2, pages 203.1-203.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Rheumatology 25:1, pages 145-156.
Crossref
Crossref